{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:30:33Z","timestamp":1793284233157,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004784","name":"Novartis Foundation for Medical-Biological Research","doi-asserted-by":"publisher","award":["23A069"],"award-info":[{"award-number":["23A069"]}],"id":[{"id":"10.13039\/501100004784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["320030_232029"],"award-info":[{"award-number":["320030_232029"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["CRSK-3_237553"],"award-info":[{"award-number":["CRSK-3_237553"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.coviro.2026.101511","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:42:02Z","timestamp":1769535722000},"page":"101511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Human autoantibodies against type I interferons in severe viral disease"],"prefix":"10.1016","volume":"74","author":[{"given":"Kevin","family":"Groen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3891-9480","authenticated-orcid":false,"given":"Benjamin G","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2026.101511_bib1","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1016\/j.cell.2025.06.044","article-title":"Interferons in health and disease","volume":"188","author":"Boehmer","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2026.101511_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.tim.2021.03.001","article-title":"Interferon system deficiencies exacerbating severe pandemic virus infections","volume":"29","author":"Stertz","year":"2021","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.coviro.2026.101511_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101511_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250164","article-title":"Autoantibodies targeting type I interferons: prevalence, mechanisms of induction, and association with viral disease susceptibility","volume":"53","author":"Hale","year":"2023","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41590-024-01815-y","article-title":"The ouroboros of autoimmunity","volume":"25","author":"Casanova","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib6","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib7","doi-asserted-by":"crossref","DOI":"10.70962\/jhi.20250031","article-title":"Prevalence and association of type I IFN autoantibodies with clinical outcomes in critically ill Brazilian COVID-19 patients","volume":"1","author":"Peduti","year":"2025","journal-title":"J Hum Immun"},{"key":"10.1016\/j.coviro.2026.101511_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s10875-022-01308-3","article-title":"Neutralizing type i interferon autoantibodies in Japanese patients with severe COVID-19","volume":"42","author":"Eto","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/jir.2023.0087","article-title":"High anti-interferon-alpha autoantibody levels in severe\/critical COVID-19 patients from Peru","volume":"43","author":"Pons","year":"2023","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.coviro.2026.101511_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001709","article-title":"Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease","volume":"20","author":"Busnadiego","year":"2022","journal-title":"PLoS Biol"},{"key":"10.1016\/j.coviro.2026.101511_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13116","article-title":"Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial","volume":"17","author":"Alotaibi","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.coviro.2026.101511_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2025.102722","article-title":"Autoantibodies to interferon alpha, nuclear antigens, cardiolipin, and beta 2 glycoprotein 1 in a Ugandan cohort and their relation to SARS-CoV-2 infection","volume":"18","author":"Epstein-Shuman","year":"2025","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.coviro.2026.101511_sbref13","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240365","article-title":"Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies","volume":"221","author":"Fernbach","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib14","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230661","article-title":"Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients","volume":"220","author":"Gervais","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib15","article-title":"Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts","author":"Gervais","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.coviro.2026.101511_bib16","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251760","article-title":"Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis","volume":"223","author":"Gervais","year":"2026","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib17","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240637","article-title":"Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in approximately 10% of patients","volume":"221","author":"Gervais","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib18","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220514","article-title":"Autoantibodies against type I IFNs in patients with critical influenza pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_sbref19","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240942","article-title":"Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease","volume":"221","author":"Gervais","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib20","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251962","article-title":"Autoantibodies neutralizing type I IFNs in a fatal case of H5N1 avian influenza","volume":"223","author":"Zhang","year":"2026","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib21","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202486","article-title":"Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib22","article-title":"Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs","volume":"218","author":"Lopez","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s10875-021-01168-3","article-title":"Interferon-alpha2 auto-antibodies in convalescent plasma therapy for COVID-19","volume":"42","author":"Raadsen","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/imcb.12495","article-title":"Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19","volume":"99","author":"Abers","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.coviro.2026.101511_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/imr.13304","article-title":"Human autoantibodies neutralizing type I IFNs: from 1981 to 2023","volume":"322","author":"Bastard","year":"2024","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coviro.2026.101511_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2504318122","article-title":"The potential impacts of human genetics on virus emergence","volume":"122","author":"Langlois","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101511_bib27","doi-asserted-by":"crossref","DOI":"10.70962\/jhi.20250019","article-title":"Case-based evidence links increased SARS-CoV-2 diversity to impaired IFN-I response in severe COVID-19","volume":"1","author":"Bussy","year":"2025","journal-title":"J Hum Immun"},{"key":"10.1016\/j.coviro.2026.101511_bib28","article-title":"Innate immune control of influenza virus interspecies adaptation via IFITM3","volume":"15","author":"Denz","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101511_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2412990122","article-title":"An atlas of protein phosphorylation dynamics during interferon signaling","volume":"122","author":"Busnadiego","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101511_bib30","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111600119","article-title":"Differential interferon-alpha subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection","volume":"119","author":"Schuhenn","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101511_bib31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10875-023-01512-9","article-title":"Autoantibodies neutralizing type I IFNs in the bronchoalveolar lavage of at least 10% of patients during life-threatening COVID-19 pneumonia","volume":"43","author":"Philippot","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101511_sbref32","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231353","article-title":"Higher COVID-19 pneumonia risk associated with anti-IFN-alpha than with anti-IFN-omega auto-Abs in children","volume":"221","author":"Bastard","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010843","article-title":"Constitutive expression and distinct properties of IFN-epsilon protect the female reproductive tract from Zika virus infection","volume":"19","author":"Coldbeck-Shackley","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2026.101511_sbref34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq1789","article-title":"Transient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19","volume":"16","author":"Babcock","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2026.101511_sbref35","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20242039","article-title":"Type I IFN autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design","volume":"222","author":"Groen","year":"2025","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1556731","article-title":"Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients","volume":"16","author":"Framil","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19","volume":"13","author":"van der Wijst","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2026.101511_bib38","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1093\/infdis\/jiae036","article-title":"Type I interferon auto-antibodies correlate with cellular immune alterations in severe COVID-19","volume":"230","author":"Strunz","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2026.101511_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-024-01708-7","article-title":"Suppression of type I interferon signaling in myeloid cells by autoantibodies in severe COVID-19 patients","volume":"44","author":"Aoki","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib40","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220258","article-title":"Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination","volume":"220","author":"Sokal","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2026.101511_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abp8966","article-title":"Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs","volume":"8","author":"Bastard","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451516","article-title":"Rapid detection of anti-IFN-alpha2 autoantibodies using a new automated VIDAS assay prototype","volume":"55","author":"Pons","year":"2025","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451325","article-title":"Highly sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodies","volume":"54","author":"Groen","year":"2024","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib44","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2402983121","article-title":"A sensitive assay for measuring whole-blood responses to type I IFNs","volume":"121","author":"Gervais","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101511_bib45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10875-021-00994-9","article-title":"Plasma exchange to rescue patients with autoantibodies against type I\u00a0interferons and life-threatening COVID-19 pneumonia","volume":"41","author":"de Prost","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10875-021-01023-5","article-title":"Interferon-beta therapy in a patient with incontinentia pigmenti and autoantibodies against type I IFNs infected with SARS-CoV-2","volume":"41","author":"Bastard","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101195","article-title":"Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74","volume":"32","author":"Potter","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.coviro.2026.101511_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 \u2014\u00a0interim WHO Solidarity Trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2026.101511_bib49","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coviro.2026.101511_sbref50","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adm8186","article-title":"Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-gamma","volume":"10","author":"Peng","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coviro.2026.101511_bib51","doi-asserted-by":"crossref","first-page":"14979","DOI":"10.1074\/jbc.M115.652156","article-title":"Structural insights into the neutralization properties of the fully human, anti-interferon monoclonal antibody sifalimumab","volume":"290","author":"Oganesyan","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2026.101511_bib52","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/pro.2729","article-title":"Structural basis of the broadly neutralizing anti-interferon-alpha antibody rontalizumab","volume":"24","author":"Maurer","year":"2015","journal-title":"Protein Sci"},{"key":"10.1016\/j.coviro.2026.101511_bib53","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2011.06.048","article-title":"Structural linkage between ligand discrimination and receptor activation by type I interferons","volume":"146","author":"Thomas","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2026.101511_bib54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2532212123","article-title":"Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis","volume":"123","author":"Gervais","year":"2026","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625726000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625726000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:19:49Z","timestamp":1780816789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625726000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":54,"alternative-id":["S1879625726000039"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101511","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human autoantibodies against type I interferons in severe viral disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101511"}}